Pfizer releases positive Phase II trial results of meningococcal B vaccine
According to the company, in both the trials ‘bivalent rLP2086’ was observed to generate bactericidal responses, a measurement of functional immune response, against diverse meningococcal serogroup B test
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.